Who are Innate Pharma S.A.'s main suppliers?

Innate Pharma S.A. (IPHA) key suppliers include: AstraZeneca PLC, AstraZeneca PLC, SANOFI, IPHYF, Arcus Biosciences, Inc. and 1 more. View the full supplier network at chainsifter.com/chain/IPHA.

Who are Innate Pharma S.A.'s major customers?

Innate Pharma S.A. (IPHA) key customers include: Novo Nordisk A/S, Novo Nordisk A/S, Arcus Biosciences, Inc., Sanofi, Sanofi and 1 more. View the full customer network at chainsifter.com/chain/IPHA.

What sector is Innate Pharma S.A. in?

Innate Pharma S.A. (IPHA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Innate Pharma S.A. Suppliers, Customers & Supply Chain (IPHA)

6Suppliers

6Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Innate Pharma S.A. (IPHA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

1Distinct source URLs

4High confidence

0.768Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Innate Pharma S.A. Suppliers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	90%	The Company has significant collaborations with AstraZeneca for the development of monalizumab and IPH5201.
AZN	AstraZeneca PLC	90%	Reciprocal relationship from AZN graph: Reciprocal relationship from IPHA graph: The Company has significant collaborations with AstraZeneca for the development of monalizumab and IPH5201.
SANOFI	SANOFI	90%	The Company also collaborates with Sanofi for the development of IPH62
IPHYF	IPHYF	72%	Reciprocal relationship from IPHYF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from IPHYF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from IPHY…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to c…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from SNYN…

Innate Pharma S.A. Customers

Ticker	Name	Confidence	Evidence
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from IPHA graph: ry platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes its lead proprietary program lacutamab, de…
NVO	Novo Nordisk A/S	72%	ry platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes its lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymp…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHA graph: rovisions of Article L. 225-248 of the French Commercial Code, the shareholders decided on May 22, 2025 to pursue th…
SNYNF	Sanofi	72%	rovisions of Article L. 225-248 of the French Commercial Code, the shareholders decided on May 22, 2025 to pursue the activities of the Company. The likelihood and amount of its future operational lo…
PREMISES-INNATE-INC	PREMISES-INNATE-INC	62%	he Company has requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtain…

Innate Pharma S.A. Debt Obligations

Instrument	Description	Confidence	Evidence
IPHA-DEBT	Debt stack $26.3M	90%	Market cache reports total debt of $26.3M.

Innate Pharma S.A. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Innate Pharma S.A..

Innate Pharma S.A. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Innate Pharma S.A..

Innate Pharma S.A. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ATOS	Atossa Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	1	['customer']
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	1	['supplier']
ANL	Adlai Nortye Ltd.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2

Innate Pharma S.A. Supply Chain